Potent endogenous cannabinoid and vanilloid receptor agonist, with no action at dopamine receptors. Selective for CB1 over CB2 receptors (Ki values are 0.25 and 12 μM respectively), and potent agonist at TRPV1 (VR1) receptors (EC50 ~ 50 nM). Metabolically stable and competitively inhibits FAAH and anandamide transport. Has cannabinoid and vanilloid actions in vivo. Also available as part of the Endocannabinoid Tocriset™.